Ascletis Reports Positive Interim Results from the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B Functional Cure
Shots:
- The company highlighted an interim result from the P-IIb expansion cohort evaluating ASC22 (SC) vs PBO in patients with CHB. Additionally, patients in both ASC22 & PBO cohorts received nucleot(s)ide analogues (NAs) as a background therapy
- The results showed that patients treated with the ASC22 cohort achieved HBsAg loss (21.1%) at the end of 24wk. treatment. The therapy was found to be safe and well-tolerated
- The company collaborated with global partners to discuss collaboration on combination therapies to achieve higher functional cure rates for HBV
Ref: PRNewswire | Image: Ascletis
Related Nesw:- Ascletis Reports the Dosing of Four Healthy Patients of ASC11 in Multiple-Dose Escalation P-I Trial for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
